Trials / Not Yet Recruiting
Not Yet RecruitingNCT07114666
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer patients following surgical resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | XH001 | mRNA neoantigen cancer vaccine |
| DRUG | Chemotherapy | Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU |
Timeline
- Start date
- 2025-08-18
- Primary completion
- 2029-08-01
- Completion
- 2030-08-01
- First posted
- 2025-08-11
- Last updated
- 2025-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07114666. Inclusion in this directory is not an endorsement.